Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab

The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab.

[1]  B. Godman,et al.  Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis , 2018, BioDrugs.

[2]  Y. Tajima,et al.  Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature , 2018, Journal of Medical Case Reports.

[3]  K. Muro,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  L. Rosen,et al.  Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars , 2017, Targeted Oncology.

[5]  T. Iida,et al.  A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab , 2016, Internal medicine.

[6]  T. Tsuzuki,et al.  The effects of bevacizumab on intestinal anastomotic healing in rabbits , 2016, Surgery Today.

[7]  S. Barni,et al.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies , 2016, Annals of surgery.

[8]  J. Lefèvre,et al.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer. , 2015, Annals of surgery.

[9]  M. Yano,et al.  Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report , 2015, International journal of surgery case reports.

[10]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[11]  C. Morosi,et al.  Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. , 2015, Critical reviews in oncology/hematology.

[12]  R. Steele,et al.  Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks , 2015, The British journal of surgery.

[13]  H. Shinozaki,et al.  Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. , 2015, Japanese journal of clinical oncology.

[14]  Yang Yao,et al.  Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups , 2014, European Journal of Clinical Pharmacology.

[15]  E. Pavlidis,et al.  Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. , 2013, World journal of gastroenterology.

[16]  D. Tyler,et al.  Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. , 2012, Journal of the American College of Surgeons.

[17]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[18]  M. Pocard,et al.  Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy. , 2011, Clinics and research in hepatology and gastroenterology.

[19]  K. Topouridou,et al.  The effect of bevacizumab on colon anastomotic healing in rats , 2010, International Journal of Colorectal Disease.

[20]  R. Barakat,et al.  Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. , 2010, Gynecologic oncology.

[21]  X Allen Li,et al.  Radiation dose-volume effects in the stomach and small bowel. , 2010, International journal of radiation oncology, biology, physics.

[22]  Shenhong Wu,et al.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. , 2009, The Lancet. Oncology.

[23]  F. Viret,et al.  Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients , 2009, Annals of Surgical Oncology.

[24]  L. Sidéris,et al.  Complications after colorectal anastomosis in a patient with metastatic rectal cancer treated with systemic chemotherapy and bevacizumab. , 2008, Canadian journal of surgery. Journal canadien de chirurgie.

[25]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[26]  S. Huerta,et al.  Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. , 2006, Current surgery.

[27]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[28]  Y. Terashima,et al.  Two Cases of Emergency Operations in Patients Undergoing Bevacizumab Treatment , 2010 .

[29]  L. Ellis,et al.  Management of bevacizumab-associated bowel perforation: a case series and review of the literature. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.